"Near Term Focus Remains on Upcoming Schizophrenia Data; Risk/Reward Remains Compelling" - Mizuho Securities Reiterates Karuna Therapeutics (KRTX) at Buy with $15 Price Target
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $190.00 price target on Karuna Therapeutics Inc. (NASDAQ: KRTX). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
